Reslizumab
Add to cart
Reslizumab is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma.
[accordions]
[accordion title= “Biological Description“]
| Description | Reslizumab is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. |
| Targets&IC50 | IL-5-dependent cell proliferation:91.1pM |
[/accordion]
[accordions]
[accordion title= “References and Literature“]
1. Liddament M, et al. Higher Binding Affinity and in vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab. Allergy Asthma Immunol Res. 2019 Mar;11(2):291-298.2. Pérez de Llano LA, et al. Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab. Allergy. 2019 Sep 4.
[/accordion]
Related Products
HOW CAN WE HELP YOU? Our specialists are to help you find the best product for your application. We will be happy to help you find the right product for the job.
TALK TO A SPECIALIST
Contact our Customer Care, Sales & Scientific Assistance
EMAIL US
Consult and asked questions about our products & services
DOCUMENTATION
Documentation of Technical & Safety Data Sheet, Guides and more..
NEWSLETTER
We gladly support you by keeping you updated on our latest products and the developments around our services.
ATLANTIS BIOSCIENCE PTE LTD
362 Upper Paya Lebar Rd, #07-15,
Singapore 534963
WeChat ID: +65 8608 0974
© 2015-2023 Atlantis Bioscience Pte Ltd. All rights reserved. Co Reg No: 201539516N